Related by context. All words. (Click for frequent words.) 68 Phase IIb clinical trials 68 alvespimycin 67 JAK inhibitor 67 Phase Ib study 66 Tarvacin TM 66 preclinically 66 Squalamine 66 JAK2 inhibitor 65 CBLC# 64 CDK inhibitors 64 Symadex 64 selective androgen receptor modulator 64 Phase #b/#a 64 oral prodrug 64 cannabinor 64 JAK inhibitors 64 vascular disrupting agents 64 EP #R 64 TRV# [001] 64 tremelimumab 64 vascular disrupting agent 64 Archexin 64 PXD# 64 SARMs 64 Guanilib 63 midstage trials 63 preclinical efficacy 63 RGB # 63 ONCONASE R 63 Nanobody 63 MEK inhibitor 63 IAP inhibitor 63 therapeutic monoclonal antibody 63 PDE4 inhibitor 63 INCB# [001] 63 teplizumab 63 glucokinase activator 63 Hedgehog antagonist 63 XmAb 63 ganetespib 63 epothilone 63 Nanobody ® 63 antiviral compounds 63 investigational hepatitis C 63 Spiegelmer ® 63 phase IIa clinical 63 Aplidin 63 TLR antagonists 62 HCV protease inhibitors 62 Cetrorelix 62 DXL# 62 Bicifadine 62 OMP #M# 62 ENMD # 62 novel peptide 62 Spiegelmer 62 AEG# 62 torezolid phosphate 62 NovaBay Aganocide compounds 62 otelixizumab 62 Onconase 62 Deforolimus 62 immunotherapeutic vaccine 62 cyclophilin inhibitors 62 PSN# [002] 62 Aurora kinase inhibitor 62 HDL Mimetic Peptide 62 mertansine 62 ATL# [001] 62 HGS# 62 ALTROPANE 62 HuMax CD4 62 GRN# 62 AP# [003] 62 tanespimycin 62 siRNA therapeutics 62 incyclinide 62 INS# [001] 62 Oglemilast 62 XmAb# 62 SMT C# 62 neratinib 62 Factor VIIa 62 enzastaurin 62 isoform selective 62 phase IIb trial 62 IAP inhibitors 62 pertuzumab 61 deforolimus 61 delafloxacin 61 TACI Ig 61 CEQ# 61 ATL# [002] 61 TRO# 61 radezolid 61 obatoclax 61 BNC# 61 haematological cancers 61 Phase Ib II 61 HuMax EGFr 61 ruxolitinib 61 elotuzumab 61 HQK 61 R#/MEM 61 GAP #B# 61 tiapamil 61 Lpathomab 61 DPX Survivac 61 ASONEP 61 Celator 61 tezampanel NGX# 61 Ceflatonin 61 nitric oxide donating 61 Tarvacin 61 riociguat 61 immunomodulatory 61 JAK2 inhibitors 61 protein kinase inhibitors 61 tezampanel 61 CRD5 61 cancer immunotherapies 61 NEUGENE 61 renin inhibitors 61 lixivaptan 61 volociximab 61 IL# PE#QQR 61 CR# vcMMAE 61 PEGylated interferon 61 novel therapeutic antibodies 61 Liprostin 61 JAK3 inhibitor 61 optimal dosing regimens 61 Curaxin 61 YONDELIS 61 cMET 61 virus HCV protease inhibitor 61 trodusquemine 61 Pimavanserin 61 resolvins 61 Plicera 61 synthetic retinoid 60 selective androgen receptor modulators 60 nanoviricides 60 PARP inhibitor 60 HCV polymerase inhibitors 60 SNT MC# 60 CCR5 antagonist 60 PNT# 60 GGF2 60 THR beta agonist 60 Azedra 60 RNA antagonists 60 NEUGENE R 60 TELINTRA 60 novel anticancer 60 bardoxolone 60 epigenetic therapies 60 trastuzumab DM1 T DM1 60 histone deacetylase inhibitor 60 PDE# inhibitors 60 forodesine 60 molecularly targeted 60 prostone 60 DepoVax 60 HuLuc# 60 RhuDex 60 orally bioavailable 60 BAY #-# 60 Phase 2a clinical trials 60 anticoagulant reversing agent 60 vivo preclinical 60 Phase #/#a 60 EGS# 60 Davanat 60 Nuvion 60 dexanabinol 60 immatics 60 Sym# 60 Nanobodies ® 60 Pertuzumab 60 exon skipping 60 AZILECT ® 60 VitiGam 60 torezolid 60 CB1 antagonists 60 Zybrestat 60 theranostic 60 Vitaxin 60 Phase III registrational 60 anti fibrotic 60 HIV integrase inhibitors 60 Mipomersen 60 BiTE 60 mGluR2 NAM 60 targeting PCSK9 60 Aganocide ® 60 OncoVEX GM CSF 60 Cloretazine ® 60 OncoVEX 60 ulimorelin 60 liposomal formulation 60 proteasome inhibitor 60 GALNS 60 entinostat 60 rxRNA 60 glucagon receptor 60 proteasome inhibitors 60 predictive biomarkers 60 BRAF inhibitor 60 CDP# 60 inhibit metastasis 60 GLPG# 60 AeroLEF TM 60 Chimigen TM 60 candidate CRLX# 60 Trofex 60 cilengitide 60 Aflibercept 60 Panzem 60 nucleoside tide 60 Phase IIa trials 60 receptor tyrosine kinase inhibitor 60 CCX# 60 genomic biomarker 60 SAR# [002] 60 R#/MEM # 60 lumiliximab 60 Debio 59 phase IIa 59 metaglidasen 59 CORT # 59 Urocidin 59 Lixivaptan 59 therapeutic monoclonal antibodies 59 AQ4N 59 Chemophase 59 Aviptadil 59 PrevOnco 59 phase IIb clinical 59 Anavex #-# 59 IMA# 59 Personalized Immunotherapy 59 polymerase inhibitors 59 PI3 kinase inhibitors 59 Amplimexon 59 vinca alkaloid 59 MEK inhibitors 59 pharmacodynamic markers 59 fosbretabulin 59 investigational HCV polymerase 59 HSP# inhibitor 59 Bevasiranib 59 HGS ETR1 59 Annamycin 59 ZFP Therapeutic 59 SIRT1 activators 59 Tarvacin Anti Viral 59 velafermin 59 PEG SN# 59 atacicept 59 GW# [003] 59 phase Ib 59 Fodosine 59 HCV antiviral 59 PROSTVAC TM 59 oral salmon calcitonin 59 NOX E# 59 tubulin inhibitor 59 LibiGel ® 59 Cinquil 59 TLK# 59 PHX# 59 JAK1 59 lomitapide 59 Phase IIB 59 LHRH antagonist 59 INT# [002] 59 TBC# 59 viral kinetics 59 Virulizin ® 59 Diamyd ® 59 SCIB1 59 vemurafenib 59 ganaxolone 59 PSMA ADC 59 Carfilzomib 59 NNR Therapeutics 59 BrachySil TM 59 depsipeptide 59 TOCOSOL Camptothecin 59 varespladib 59 phase IIb 59 kinase inhibition 59 Zenvia ™ 59 ocrelizumab 59 brostallicin 59 novel VDA molecule 59 pharmacological chaperone 59 ostarine 59 Behcet uveitis 59 pradefovir 59 PRT# 59 Insegia 59 Tyrima 59 Desmoteplase 59 ProSavin 59 Panzem R NCD 59 AVE# 59 favorable pharmacokinetic profile 59 CLORETAZINE TM VNP#M 59 romidepsin novel 59 reslizumab 59 TPI ASM8 59 Atiprimod 59 OHR/AVR# 59 Xanafide 59 SYN# 59 ZK EPO 59 Dacogen decitabine 59 Exherin TM 59 anticancer therapies 59 biologic therapeutics 59 anticancer compound 59 BLA filing 59 Asentar 59 Phase #b/#a trial 59 personalized immunotherapy 59 Pancreate 59 LymphoStat B TM 59 Quinamed 59 farletuzumab 59 placebo controlled clinical 59 SuperAntibody 59 Lu AA# 58 OvaRex ® MAb 58 Trandolapril 58 Exelixis compounds 58 docetaxel Taxotere R 58 HCD# [002] 58 multicenter Phase II 58 ImQuest 58 GRNCM1 58 TLR8 agonist 58 Chrysalin 58 Surfaxin LS 58 talabostat 58 imexon 58 Phase Ib clinical 58 ANAVEX #-# [003] 58 PI3K/Akt pathway inhibitor 58 TLR9 agonists 58 Altastaph 58 IMC #B 58 Muraglitazar 58 potent anticancer 58 Androxal TM 58 oral antiviral 58 Lisofylline LSF 58 predictive toxicology 58 ALN PCS 58 PSN# [001] 58 GLP toxicology studies 58 Cytolin R 58 liprotamase 58 Thiovir 58 vidofludimus 58 oncolytic 58 BRAF inhibitors 58 acyclovir Lauriad R 58 Alzhemed TM 58 CB2 selective receptor agonist 58 ELACYT 58 immunotherapeutic approaches 58 MEK inhibitor RDEA# 58 ImmunoVEX HSV2 58 Safinamide 58 Angiocept 58 squalamine 58 non nucleoside 58 BHT DNA 58 oncolytic vaccine 58 pomalidomide 58 HCV polymerase inhibitor 58 romazarit 58 OMP #R# 58 non nucleoside HCV 58 Ostarine 58 Immunotherapeutic 58 novel immunotherapeutic 58 ozarelix 58 thiazolides 58 Maxy G# 58 adipiplon 58 investigational humanized monoclonal antibody 58 MT#/MEDI-# 58 human microdosing 58 AZX# 58 ATL/TV# 58 non nucleoside inhibitor 58 Radezolid 58 Ampakine 58 TKM ApoB 58 Triolex 58 VEGF inhibitors 58 siRNA therapeutic 58 OncoVex 58 Zolinza 58 Tesetaxel 58 GPCR targets 58 eniluracil 58 multi kinase inhibitor 58 oral PTH 58 NXL# 58 AMD# [003] 58 antiangiogenic agents 58 AMPK activators 58 NP2 Enkephalin 58 Neo Kidney Augment ™ 58 VEGF Trap 58 adrenergic regulation 58 RNAi therapeutic targeting 58 Traficet EN 58 Nanobody R 58 rBChE 58 Syntonix 58 INCB# [003] 58 Cethrin R 58 novel peptides 58 Campath ® 58 TriRima 58 faropenem 58 YONDELIS R 58 integrase inhibitor 58 SPC# [001] 58 Hsp# inhibition 58 oral taxane 58 Phase #b/#a clinical 58 Alocrest 58 preclinical compounds 58 Cloretazine R 58 Golimumab 58 small molecule activators 58 vivo validation 58 Solazed TM 58 HIV integrase inhibitor 58 ESBA# 58 NeuroVax 58 antisense therapeutics 58 Omacetaxine 58 clinical pharmacology studies 58 antitumor 58 Troxatyl 58 davunetide intranasal AL 58 teriflunomide 58 PCK# 58 anticancer agents 58 targeted radiotherapeutic 58 compound INCB# 58 HuMax TAC 58 triphendiol 58 MabThera rituximab 58 aurora kinase 58 vivo potency 58 LHRH antagonists 58 GAMMAGARD 58 NV1FGF 58 antibody MAb 58 phase IIb study 58 multitargeted 58 Adnectin 58 IMiD 58 GVAX ® 58 preclinical 58 HDL Selective Delipidation 58 monoclonal antibody therapies 58 outlicensing 58 Velcade bortezomib 58 OMAPRO 58 Tesmilifene 58 trial evaluating PRX# 58 IND submission 58 flavopiridol 58 GSK # 58 NEUMUNE 58 cyclophilin inhibitor 58 monoclonal antibody therapeutics 58 REOLYSIN ® 58 A3 adenosine receptor 58 Aganocide R 58 CMV vaccine 58 PI3K inhibitor 58 TG# [003] 58 Litx 58 CCR5 inhibitor 58 REP# 58 PNP inhibitor 58 PDX pralatrexate 58 Trofex TM 58 Blinatumomab 58 ALN TTR 58 indibulin 58 NGX# 57 LBH# 57 AKT inhibitor 57 romidepsin 57 nicotinic alpha 7 57 NEUGENE antisense 57 antisense drug 57 BAL# [002] 57 HDACi 57 ThGRF 57 eprotirome 57 LAF# 57 Tasimelteon 57 systemic RNAi 57 mitogen activated ERK kinase 57 Phase 1a clinical 57 Myocet 57 PDE# 57 bortezomib Velcade 57 dacetuzumab 57 anti CD# antibodies 57 Posiphen 57 USL# 57 dasatinib Sprycel 57 immunoregulation 57 NPC 1C 57 Stimuvax R 57 huN# DM1 57 allosteric modulation 57 pramlintide metreleptin combination 57 humanised monoclonal antibody 57 ospemifene 57 PRTX 57 selective S#P# receptor agonist 57 LEP ETU 57 RhuDex R 57 ibudilast 57 lapatinib Tykerb 57 Kamada AAT 57 rifalazil 57 Panzem R 57 sorafenib Nexavar 57 molecular imaging radiopharmaceutical 57 sulodexide 57 celgosivir 57 Ramoplanin 57 GFT# 57 CRLX# 57 PrevOnco ™ 57 ON #.Na 57 vorinostat 57 GMX# 57 Nexavar sorafenib 57 mTOR inhibition 57 Stapled Peptide 57 Zoraxel 57 Cloretazine 57 pharmacokinetic PK study 57 immunotherapeutics 57 angiogenesis inhibitor 57 MAXY G# 57 dose escalation Phase 57 TRAIL receptor antibodies 57 kinase inhibitors 57 bevacizumab Avastin ® 57 Azedra TM 57 MKC# MKC# PP 57 gepirone ER 57 protein kinase inhibitor 57 STEDESA 57 BCX# 57 nonclinical studies 57 Zemiva TM 57 Cylene 57 histone deacetylase HDAC inhibitor 57 Allovectin 7 ® 57 thalidomide Thalomid 57 cediranib 57 SUCCEED trial 57 Panzem NCD 57 MYCAMINE 57 Vilazodone 57 ALN TTR# 57 Optiquel ™ 57 histone deacetylase HDAC inhibitors 57 Gleevec imatinib mesylate 57 GPR# agonist 57 gefitinib Iressa 57 Synavive 57 insulin sensitizer 57 Anticalin 57 Zenvia Phase III 57 CYT# potent vascular disrupting 57 NTDDS 57 antimetabolite 57 Fx #A 57 preclinical pharmacokinetic 57 cystinosis patients 57 nucleoside analog 57 Curaxin CBLC# 57 Azixa 57 BAL# [001] 57 multiple myeloma MM 57 seliciclib CYC# 57 trastuzumab DM1 57 maribavir 57 IND enabling 57 Hematide TM 57 AzaSite Plus 57 KNS # 57 cardiometabolic 57 PLK1 SNALP 57 pharmacodynamic properties 57 Akt inhibitor 57 MAXY alpha 57 StemEx R 57 GSK# [002] 57 postoperative ileus POI 57 ixabepilone 57 FGFR 57 Neo Kidney Augment 57 DCCR 57 antitumoral 57 laninamivir 57 Toraymyxin TM 57 vosaroxin 57 promising anticancer 57 Hedgehog pathway inhibitor 57 CA4P 57 rALLy clinical trial 57 clevidipine 57 ALK inhibitors 57 ACV1 57 COX Inhibiting Nitric Oxide 57 telaprevir VX 57 drug GAP #B# 57 evaluating satraplatin 57 epigenetic therapeutics 57 ANAVEX 57 Celacade TM 57 motesanib 57 RPL# 57 Dacogen injection 57 Enzastaurin 57 mapatumumab 57 HuCAL antibodies 57 Telintra 57 TÎ ² 4 57 anticancer therapeutics 57 ELND-#/AZD-# 57 isavuconazole 57 FluINsure 57 FOLOTYN ® 57 CRMD# 57 AMPAKINE R 57 Alequel TM 57 Rigel R# 57 Phase IIIb clinical 57 hypoxic tumors 57 epothilones 57 hepatitis B vaccine Heplisav 57 MORAb 57 Abiraterone acetate 57 GeoVax vaccine 57 immunological diseases 57 antifolates 57 bioequivalency 57 REG1 57 LSI #P 57 Lovaxin C 57 beta 1a 57 Dapagliflozin 57 immune modulating 57 brivaracetam 57 inhaled AAT 57 Rasagiline 57 Ketotransdel 57 tafamidis 57 NVA# 57 molecular biomarkers 57 sirtuin inhibitors 57 preclinical studies 57 Relovair 57 Silodosin 57 ICA # 57 Tykerb lapatinib 57 Viprovex TM 57 Galenea 57 carbapenem 57 Oncotype DX colon cancer 57 Genz # 57 Allovectin 7 R 57 MDS AML 57 EGFR HER 57 Phase 1b trial 57 RhuDex ® 57 Dalbavancin 57 LE DT 57 Nalmefene 57 investigational therapies 57 Phase 2a clinical 57 custirsen 57 anti CD3 antibody 57 Phase IIb III 57 orally inhaled migraine 57 Zemplar Capsules 57 Telatinib 57 selective inhibitors 57 AMPAKINE 57 prophylactic vaccine 57 cathepsin K inhibitor 57 class mGluR5 inhibitor 56 ACAPODENE 56 sitaxsentan 56 bicifadine 56 Memryte 56 Ataluren 56 Anti angiogenic 56 talactoferrin 56 IgG1 antibody 56 Phase 2a trial 56 ARIKACE ™ 56 PD LID 56 HepeX B 56 PET tracers 56 Vernakalant 56 OvaRex R 56 LEVADEX ™ 56 Neugene 56 PRX # 56 midstage clinical 56 SNALP technology 56 KRN# 56 ProMune 56 CG# [003] 56 PROCHYMAL 56 MOZOBIL 56 Phase IIb trials 56 commercialize OncoGenex lead 56 molecularly targeted therapies 56 tyrosine kinase inhibitor 56 small molecule defensin 56 OvaRex 56 GeneICE 56 Pyridorin 56 visilizumab 56 novel histone deacetylase 56 Preclinical studies suggest 56 HCV protease inhibitor 56 antiproliferative effects 56 Aurexis 56 tramiprosate Alzhemed TM 56 OXi# 56 Ophthotech 56 Pervasis 56 Vaccinex 56 nanoviricide 56 Dasatinib 56 PANVAC VF 56 zileuton 56 MyVax ® 56 MMP inhibitors 56 PF # [002] 56 Elocalcitol 56 Romidepsin 56 Mpex 56 XL# XL# XL# XL# 56 Homspera 56 RIGScan CR 56 novel immunomodulatory 56 Sphingomab 56 OMNARIS HFA 56 Xcytrin R 56 Fabry Disease 56 anti amnesic 56 EyeGate 56 PEP# [003] 56 TOCOSOL 56 receptor inhibitor 56 nalbuphine ER 56 pivotal bioequivalence 56 ITAX 56 P#X# antagonist 56 Revimmune 56 LAS# [002] 56 NTx TM -# 56 ReN# 56 Adentri 56 nanopharmaceutical 56 RNAi therapeutic 56 BRIM2 56 Trovax 56 Atu# 56 MGd 56 NexACT 56 Aurora Kinase 56 deacetylase inhibitors 56 Saforis 56 Smac mimetics 56 tranilast 56 dirucotide 56 BEMA TM Fentanyl 56 evaluating tivozanib 56 novel oral anticoagulant 56 huC# DM4 56 Gemin X 56 radiolabeled TM# 56 PREOS R 56 TNF alpha inhibitor 56 hematological indications 56 MGCD# [001] 56 BrachySil 56 GLYX 56 IRX 2 56 direct thrombin inhibitors 56 MLN# 56 Cutanea 56 omacetaxine mepesuccinate 56 SERMs 56 Neuradiab 56 novel antiviral therapeutics 56 Phase 1b clinical trials 56 EndoTAG TM -1 56 Tanespimycin 56 Zingo TM 56 Cintredekin Besudotox 56 Onalta 56 humanized antibody 56 Itopride 56 orally administered inhibitor 56 Sphingomab TM 56 Phase lll 56 CTAP# Capsules 56 Nanobodies 56 Proxinium TM 56 Phenoptin 56 BRIM3 56 macitentan 56 XL# XL# 56 HSP# inhibitors 56 prodrugs 56 oral anticancer 56 Multimeric 56 Hedgehog inhibitor 56 HIF PH inhibitors 56 Vidaza azacitidine 56 Restanza 56 CINOD 56 preclinical toxicology 56 selective orally bioavailable 56 RAV# 56 Androxal ® 56 ART# 56 trastuzumab Herceptin 56 MGN# 56 CD# antibody [001] 56 ANG# 56 chemopreventive agent 56 preclinical pharmacology 56 telomerase therapeutic 56 BZL# 56 liposomal ciprofloxacin 56 Zalypsis 56 trastuzumab emtansine T DM1 56 XP #L 56 dexpramipexole 56 CCR5 mAb 56 zanolimumab 56 Phase Ib 56 intranasal insulin product 56 methylnaltrexone 56 Hsp# Inhibitor 56 Cortex AMPAKINE 56 GSK# [001] 56 Nasulin 56 alagebrium 56 GPR# agonists 56 Valdoxan 56 angiogenesis inhibition 56 Fibrillex 56 BLyS specific 56 Mepact 56 phase IIb III 56 anti secretory 56 BCR ABL inhibitors 56 Protexia R 56 Intravail ® 56 rhFVIIa 56 Zarnestra 56 BiTE antibody 56 afamelanotide 56 PEGylated 56 Cogane 56 resolvin 56 EGFR inhibitors 56 Hyphanox 56 antitumor effect 56 Cx# [002] 56 inhibitor RG# 56 phase 2a 56 Phase III randomized controlled 56 erlotinib Tarceva ® 56 Denufosol 56 generation purine nucleoside 56 IMiDs ® 56 UPLYSO 56 PDE7 56 biomarker identification 56 TLR agonists 56 Homspera TM 56 midstage clinical trials 56 DepoVax ™ 56 antifibrotic 56 DACH platinum 56 CobaCyte 56 SAR# [004] 56 confirmatory Phase III 56 Unit Dose Budesonide 56 MyVax R 56 OZURDEX ® 56 CCR9 antagonist 56 canakinumab 56 Cotara ® 56 investigational protease inhibitor 56 Aurograb 56 PDGF receptor 56 Hedgehog agonist 56 PDE7 inhibitors 56 selective estrogen receptor modulator 56 Elagolix 56 TOLAMBA 56 maturation inhibitor 56 CINQUIL 56 tkRNAi 56 zileuton CR 56 Aryplase 56 ELND# 56 ataluren 56 LCP AtorFen 56 antiangiogenesis 56 MAGE A3 ASCI 56 Excellarate TM 56 therapeutic armamentarium 56 TransVax ™ 56 Shigamabs ® 56 ProLindac 56 Firazyr ® 56 Urocortin 2 56 Marqibo TM 56 anticancer agent 56 Glypromate 56 neovascular diseases 56 recombinant enzyme 56 small molecule tyrosine 56 mimetic compounds 56 mda 7 56 DEB# 56 Interferon alpha 56 potent anti angiogenic 56 SUTENT ® 56 anti angiogenic agents 56 Seliciclib 56 ocular formulation 55 RNAi therapeutic targeting PCSK9 55 fusion inhibitor 55 ISIS # 55 PhG alpha 1 55 Aquinox 55 inhibit angiogenesis 55 Interferon beta 55 ALN VSP 55 oncolytic virus 55 alemtuzumab Campath 55 Microplasmin 55 DOS# 55 ORMD 55 RezularTM 55 PS# [001] 55 nucleoside analogues 55 intranasal delivery 55 biotherapy 55 Diamyd R 55 TOPIGEN 55 Anticalins 55 Prodarsan ® 55 Charlesson 55 anti infective treatments 55 Icatibant 55 Viprinex 55 SGLT inhibitors 55 allosteric modulator 55 histamine dihydrochloride 55 protein homeostasis 55 Olaparib 55 Capesaris 55 ADME properties 55 canagliflozin 55 apricitabine ATC